A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: Part 2

Alternative Medicine Review

Volumn 15, Issue 4, 2010, Pages 313-328

  Kelly, Gregory S ^a  

^a NONE

Author keywords

Anti aging; Antiaging; Cancer; Fatty liver; Insulin resistance; Longevity; Metabolic; Neurological; Niacin; Nicotinamide; Obesity; Resveratrol; SIR; SIRT; Sirtuins; Steatosis; Vitamin B3; Weight loss

Indexed keywords

MELATONIN; QUERCETIN; RESVERATROL; SIRTUIN; ENZYME ACTIVATOR; PHENOL DERIVATIVE; STILBENE DERIVATIVE;

AGING; CARDIOVASCULAR DISEASE; FATTY LIVER; HUMAN; LONGEVITY; MEDICAL LITERATURE; MEDICAL RESEARCH; METABOLIC SYNDROME X; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; NUTRITION; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; BIOAVAILABILITY; DRUG EFFECT; METABOLISM;

AGING; BIOLOGICAL AVAILABILITY; CARDIOVASCULAR DISEASES; ENZYME ACTIVATORS; HUMANS; LONGEVITY; NEOPLASMS; NERVOUS SYSTEM DISEASES; OBESITY; PHENOLS; SIRTUINS; STILBENES;

EID: 79952265133     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Vinciguerra M, Fulco M, Ladurner A, et al. SirT1 in muscle physiology and disease: lessons from mouse models. Dis Model Mech 2010;3:298-303.
2. Li Y, Xu W, McBurney MW, Longo VD. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab 2008;8:38-48. (Pubitemid 351859225)
3. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425:191-196. (Pubitemid 37150899)
4. Kaeberlein M, McDonagh T, Heltweg B, et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 2005;280:17038-17045. (Pubitemid 41389166)
5. Wood JG, Rogina B, Lavu S, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004;430:686-689. (Pubitemid 39061685)
6. Bass TM, Weinkove D, Houthoofd K, et al. Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech Ageing Dev 2007;128:546-552. (Pubitemid 47498522)
7. Zou S, Carey JR, Liedo P, et al. The prolongevity effect of resveratrol depends on dietary composition and calorie intake in a tephritid fruit fly, Exp Gerontol 2009;44:472-476.
8. Valenzano DR, Terzibasi E, Genade T, et al. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 2006;16:296-300. (Pubitemid 43190229)
9. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-342. (Pubitemid 44764104)
10. Barger JL, Kayo T, Vann JM, et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008;3:e2264.
11. Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008;8:157-168.
12. Yokozawa T, Lee YA, Zhao Q, et al. Persimmon oligomeric proanthocyanidins extend life span of senescence-accelerated mice. J Med Food 2009;12:1199-1205.
13. Pietsch K, Saul N, Menzel R, et al. Quercetin mediated lifespan extension in Caenorhabditis elegans is modulated by age-1, daf-2, sek-1 and unc-43. Biogerontology 2009;10:565-578.
14. Gutierrez-Cuesta J, Tajes M, Jimenez A, et al. Evaluation of potential pro-survival pathways regulated by melatonin in a murine senescence model. J Pineal Res 2008;45:497-505.
15. Liang F, Kume S, Koya D. SIRT1 and insulin resistance. Nat Rev Endocrinol 2009;5:367-373.
16. Yoshizaki T, Milne JC, Imamura T, et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 2009;29:1363-1374.
17. Qiao L, Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-C/EBPalpha transcriptional complex. J Biol Chem 2006;281:39915-39924. (Pubitemid 46041795)
18. Wang H, Qiang L, Farmer SR. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol Cell Biol 2008;28:188-200.
19. Cakir I, Perello M, Lansari O, et al. Hypothalamic Sirt1 regulates food intake in a rodent model system. PLoS One 2009;4:e8322.
20. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004;429:771-776. (Pubitemid 38833129)
21. Ramadori G, Lee CE, Bookout AL, et al. Brain SIRT1: anatomical distribution and regulation by energy availability. J Neurosci 2008;28:9989-9996.
22. Chen D, Steele AD, Lindquist S, Guarente L. Increase in activity during calorie restriction requires Sirt1. Science 2005;310:1641. (Pubitemid 41780779)
23. Banks AS, Kon N, Knight C, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 2008;8:333-341.
24. Bordone L, Cohen D, Robinson et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 2007;6:759-767 (Pubitemid 350131044)
25. Pfluger PT, Herranz D, Velasco-Miguel S, et al. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 2008;105:9793-9798. (Pubitemid 352031379)
26. Sun C, Zhang F, Ge X, et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007;6:307-319. (Pubitemid 47468091)
27. Bordone L, Motta MC, Picard F, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 2006;4:e31.
28. Moynihan KA, Grimm AA, Plueger MM, et al. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab 2005;2:105-117.
29. Ramsey KM, Mills KF, Satoh A, Imai S. Age associated loss of Sirt1 mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell 2008;7:78-88.
30. Li X, Zhang S, Blander G, et al. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 2007;28:91-106. (Pubitemid 47531974)
31. Jing E, Gesta S, Kahn CR. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab 2007;6:105-114. (Pubitemid 47163621)
32. Hirschey MD, Shimazu T, Goetzman E, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010;464:121-125.
33. Shi T, Wang F, Stieren E, Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in blown adipocytes. J Biol Chem 2005;280:13560-13567. (Pubitemid 40517248)
34. Ahuja N, Schwer B, Carobbio S, et al. Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. J Biol Chem 2007;282:33583-33592. (Pubitemid 350159524)
35. Zhong L, D'Urso A, Toiber D, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif 1alpha. Cell 2010;140:280-293.
36. Kanfi Y, Peshti V, Gil R, et al. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell 2010;9:162-173.
37. Pedersen SB, Ølholm J, Paulsen SK, et al. Low Sirt1 expression, which is upregulated by fasting, in human adipose tissue from obese women. Int J Obes (Lond) 2008;32:1250-1255.
38. Rutanen J, Yaluri N, Modi S, et al. SIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity. Diabetes 2010;59:829-835.
39. de Kreutzenberg SV, Ceolotto G, Papparella I, el al. Downregulalion of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes 2010;59:1006-1015.
40. Heilbronn LK, Civitarese AE, Bogacka I, et al. Glucose tolerance and skeletal muscle gene expression in response to alternate day fasting. Obes Res 2005;13:574-581.
41. Capel F, Viguerie N, Vega N, et al. Contribution of energy restriction and macranutrient composition to changes in adipose tissue gene expression during dietary weight-loss programs in obese women. J Clin Endocrinol Metab 2008;93:4315-4322. (Pubitemid 352789527)
42. Bai L, Pang WJ, Yang YJ, Yang GS. Modulation of Sirt1 by resveratrol and nicotinamide alters proliferation and differentiation of pig preadipocytes. Mol Cell Biochem 2008;307:129-140. (Pubitemid 350238655)
43. Shan T, Wang Y, Wu T, et al. Porcine sirtuin 1 gene clone, expression pattern, and regulation by resveratrol. J Anim Sci 2009;87:895-904.
44. Wang GL, Fu YC, Xu WC, et al. Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun 2009;380:644-649.
45. Bäckesjö CM, Li Y, Lindgren U, Haldosén LA. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res 2006;21:993-1007.
46. Breen DM, Sanli T, Giacca A, Tsiani E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK Biochem Biophys Res Commun 2008;374:117-122.
47. Lee JH, Song MY, Song EK, et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 2009;58:344-351.
48. Um JH, Park SJ, Kang H, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010;59:554-563.
49. Purushotham A, Schug TT, Li X. SIRT1 performs a balancing act on the tight-rope toward longevity. Aging (Albany NY) 2009;1:669-673.
50. Xu F, Gao Z, Zhang J, et al. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the Sirt1+/- mice: a role of lipid mobilization and inflammation. Endocrinology 2010. [Epub ahead of print]
51. Escande C, Chini CC, Nin V, et al. Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high fat diet induced liver steatosis in mice. J Clin Invest 2010;120:545-558.
52. Deng XQ, Chen LL, Li NX. The expression of SIRTl in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int 2007;27:708-715.
53. Yamazaki Y, Usui I, Kanatani Y, et al. Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. Am J Physiol Endocrinol Metab 2009. [Epub ahead of print]
54. Hou X, Xu S, Maitland-Toolan KA, et al. SIRT1 regulates hepalocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008;283:20015-20026.
55. Ajmo JM, Liang X, Rogers CQ, et al. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 2008;295:G833-G842.
56. Lieber CS, Leo MA, Wang X, Decarli LM. Effect of chronic alcohol consumption on hepatic SIRT1 and PGC-1alpha in rats. Biochem Biophys Res Commun 2008;370:44-48.
57. Oliva J, French BA, Li J, et al. Sirt1 is involved in energy metabolism: the role of chronic ethanol feeding and resveratrol. Exp Mol Pathol 2008;85:155-159.
58. You M, Cao Q, Liang X, et al. Mammalian sirtuin 1 is involved in the protective action of dietary saturated fat against alcoholic fatty Liver in mice. J Nutr 2008;138:497-501. (Pubitemid 351355247)
59. You M, Liang X, Ajmo JM, Ness GC. Involvement of mammalian sirtuin 1 in the action of ethanol in the liver. Am J Physiol Gastrointest Liver Physiol 2008;294:G892-G898. (Pubitemid 351520077)
60. Shi T, Fan GQ, Xiao SD. SIRT3 reduces lipid accumulation via AMPK activation in human hepatic cells. J Dig Dis 2010;11:55-62.
61. Palacios OM, Carmona JJ, Michan S, et al. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging (Albany NY) 2009;1:771-783.
62. Costa Cdos S, Hammes TO, Rohden F, et al. SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis. Obes Surg 2010;20:633-639.
63. Balestrieri ML, Rienzo M, Felice F, et al. High glucose downregulates endothelial progenitor cell number via SIRT1. Biochim Biophys Acta 2008;1784:936-945.
64. Potente M, Ghaeni L, Baldessari D, et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 2007;21:2644-2658. (Pubitemid 47607673)
65. Mattagajasingh I, Kim CS, Naqvi A, et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 2007;104:14855-14860. (Pubitemid 350003232)
66. Orimo M, Minamino T, Miyauchi H, et al. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler Thromb Vasc Biol 2009;29:889-894.
67. Arunachalam G, Yao H, Sundar IK, et al. SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol. Biochem Biophys Res Commun 2010;393:66-72.
68. Gracia-Sancho J, Villarreal G Jr, Zhang Y, Garcia-Cardena G. Activation of SIRT1 by resveratrol induces KLF2 expression conferring an endothelial vasoprotective phenotype. Cardiovasc Res 2010;85:514-519.
69. Miyazaki R, Ichiki T, Hashimoto T, et al. SIRT1, a longevity gene, downregulates angiotensin 11 type 1 receptor expression in vascular smooth muscle cells. Arterioscler thromb Vasc Biol 2008;28:1263-1269.
70. Cardellini M, Menghini R, Martelli E, et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 2009;58:2396-2401.
71. Sundaresan NR, Samant SA, Pillai VB, et al. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol 2008;28:6384-6401.
72. Rajamohan SB, Pillai VB, Gupta M, et al. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol 2009;29:4116-4129.
73. Tanno M, Kuno A, Yano T, et al. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem 2010;285:8375-8382.
74. Sundaresan NR, Gupta M, Kim G, et al. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a dependent antioxidant defense mechanisms in mice. J Clin Invest 2009;119:2758-2771.
75. Sulaiman M, Matta MJ, Sunderesan NR, et al. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2010;298:H833-H843.
76. Chen CJ, Yu W, Fu YC, et al. Resveratrol protects cardiomyocytes from hypoxia induced apoptosis through the SIRT1-FoxO1 pathway. Biochem Biophys Res Commun 2009;378:389-393.
77. Danz ED, Skramsted J, Henry N, et al. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 2009;46:1589-1597.
78. Mukherjee S, Lekli T, Gurusamy N, et al. Expression of the longevity proteins by both red and white wines and their cardioprotective components, resveratrol, tyrosol, and hydroxytyrosol. Free Radic Biol Med 2009;46:573-578.
79. Yoshida Y, Shioi T, Izumi T. Resveratrol ameliorates experimental autoimmune myocarditis. Circ J 2007;71:397-404. (Pubitemid 46409545)
80. Alcendor RR, Gao S, Zhai P, et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007;100:1512-1521. (Pubitemid 46834764)
81. Ahn BH, Kim HS, Song S, et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci U S A 2008;105:14447-14452.
82. Vakhrusheva O, Smolka C, Gajawada P, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res 2008;102:703-710. (Pubitemid 351457857)
83. Pfister JA, Ma C, Morrison BE, D'Mello SR. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS One 2008;3:e4090.
84. Zakhary SM, Ayubcha D, Dileo JN, et al. Distribution analysis of deacetylase SIRT1 in rodent and human nervous systems. Anat Rec (Hoboken) 2010. [Epub ahead of print]
85. Chen D, Steele AD, Hutter G, et al. The role of calorie restriction and SIRT1 in prion-mediated neurodegeneration. Exp Gerontol 2008;43:1086-1093.
86. Liu D, Pitta M, Mattson MP. Preventing NAD(+) depletion protects neurons against excitotoxicity: bioenergetic effects of mild mitochondrial uncoupling and caloric restriction. Ann N Y Acad Sci 2008;1147:275-282.
87. Qin W, Yang T, Ho L, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calone restriction. J Biol Chem 2006;281:21745-21754. (Pubitemid 44181878)
88. Kakefuda K, Fujita Y, Oyagi A, et al. Sirtuin 1 overexpression mice show a reference memory deficit, but not neuroprotection. Biochem Biophys Res Commun 2009;387:784-788.
89. Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007;26:3169-3179. (Pubitemid 47057498)
90. Julien C, Tremblay C, Emond V, et al. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 2009;68:48-58.
91. Voelter-Mahlknecht S, Ho AD, Mahlknecht U. FISH-mapping and genomic organization of the NAD-dependent histone deacetylase gene, Sirtuin 2 (Sirt2). Int J Oncol 2005;27:1187-1196.
92. Tang BL, Chua CE. SIRT2, tubulin deacetylation, and Oligodendroglia differentiation. Cell Motil Cytoskeleton 2008;65:179-182. (Pubitemid 351323739)
93. Southwood CM, Peppi M, Dryden S, et al. Microtubule deacetylases. SirT2 and HDAC6, in the nervous system. Neurochem Res 2007;32:187-195. (Pubitemid 46238864)
94. Harting K, Knoll B. SIRT2-mediated protein deacetylation: an emerging key regulator in brain physiology and pathology. Eur J Cell Biol 2010;89:262-269.
95. Peck B, Chen CY, Ho KK, et al. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 2010;9:844-855.
96. North BJ, Marshall BL, Borra MT, et al. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 2003;11:437-444. (Pubitemid 36293837)
97. Pandithage R, Lilischkis R, Harting K, et al. The regulation of SIRT2 function by cydin-dependent kinases affects cell motility. J Cell Biol 2008;180:915-929. (Pubitemid 351398419)
98. Inoue T, Hiratsuka M, Osaki M, et al. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 2007;26:945-957.
99. Li W, Zhang B, Tang J, et al. Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through deacetylating alpha-tubulin. J Neurosci 2007;27:2606-2616. (Pubitemid 46393594)
100. Luthi-Carter R, Taylor DM, Pallos J, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci U S A 2010;107:7927-7932.
101. Outeiro TF, Kontopoulos E, Altmann SM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007;317:516-519. (Pubitemid 47196116)
102. Liu D, Gharavi G, Pitta M, et al. Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons. Neuromolecular Med 2009;11:28-42.
103. Chong ZZ, Maiese K. Enhanced tolerance against early and late apoptotic oxidative stress in mammalian neurons through nicotinamidase and sirtuin mediated pathways. Curr Neurovasc Res 2008;5:159-170.
104. Raval AP, Dave KR, Pérez-Pinzón MA. Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab 2006;26:1141-1147. (Pubitemid 44268176)
105. Della-Morte D, Dave KR, DeFazio RA, et al. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience 2009;159:993-1002.
106. Suzuki K, Koike T. Resveratrol abolishes resistance to axonal degeneration in slow Wallerian degeneration (WIdS) mice: activation of SIRT2, an NAD-dependent tubulin deacetylase. Biochem Biophys Res Commun 2007;359:665 671.
107. Tajes M, Gutierrez-Cuesta J, Ortuño-Sahagun D, et al. Anti-aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway. J Pineal Res 2009;47:228-237.
108. Chang HM, Wu UI, Lan CT. Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleep-deprived rats. J Pineal Res 2009;47:211-220.
109. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004;305:1010-1013. (Pubitemid 39071777)
110. Green KN, Steffan JS, Martinez-Coria H, et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231 phosphotau. J Neurosci 2008;28:11500-11510.
111. Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci 2009;5:147-152.
112. Bradbury CA, Khanim FL, Hayden R, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005;19:1751-1759. (Pubitemid 41486152)
113. Cha FJ, Noh SJ, Kwon KS, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 2009;15:4453-4459.
114. Hida Y, Kubo Y, Murao K, Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res 2007;299:103-106. (Pubitemid 46669407)
115. Huffman DM. Grizzle WE, Bamman MM, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007;67:6612-6618.
116. Jung-Hynes B, Nihal M, Zhong W, Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 2009;284:3823-3832.
117. Kabra N, Li Z, Chen L, et al. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 2009;284:18210-18217.
118. Stunkel W, Peh BK, Tan YC, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2007;2:1360-1368. (Pubitemid 350176266)
119. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004;303:2011-2015. (Pubitemid 38393275)
120. Li S, Banck M, Mujtaba S, et al. p53-Induced growth arrest is regulated by the mitochondrial SirT3 deacetylase. PLoS One 2010;5:e10486.
121. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001;107:137-148. (Pubitemid 33035941)
122. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-159. (Pubitemid 33035942)
123. Jung-Hynes B, Ahmad N. Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle 2009;8:1478-1483.
124. Yamakuchi M, Lowenstein CJ. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 2009;8:712-715.
125. Zhao W, Kruse JP, Tang Y, et al. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 2008;451:587-590. (Pubitemid 351186268)
126. Firestein R, Blander G, Michan S, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008;3:e2020.
127. Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008;14:312-323.
128. Wang RH, Zheng Y, Kim HS, et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell 2008;32:11-20.
129. Chua KF, Mostoslavsky R, Lombard DB, et al. Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab 2005;2:67-76. (Pubitemid 43239826)
130. Oberdoerffer P, Michan S, McVay M, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008;135:907-918.
131. Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation, PLoS Genet 2006;2:e40.
132. Allison SJ, Milner J. SIRT3 is pro apoptotic and participates in distinct basal apoptotic pathways. Cell Cycle 2007;6:2669-2677. (Pubitemid 350224051)
133. Kim HS, Patel K, Muldoon-Jacobs K, et al. SIRT3 is a mitochondria localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010;17:41-52.
134. Ashraf N, Zino S, Macintyre A, et al. Altered sirtuin expression is associated with node positive breast cancer. Br J Cancer 2006;95:1056-1061. (Pubitemid 44606833)
135. Schlicker C, Gertz M, Papatheodorou P, et al. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J Mol Biol 2008;382:790-801.
136. Tennen RI, Berber E, Chua KF. Functional dissection of SIRT6: identification of domains that regulate histone deacetylase activity and chromatin localization. Mech Ageing Dev 2010;131:185-192.
137. McCord RA, Michishita E, Hong T, et al. SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging (Albany NY) 2009;1:109-121.
138. Kawahara TL, Michishita E, Adler AS, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 2009;136:62-74.
139. Lombard DB. Sirtuins at the breaking point: SIRT6 in DNA repair. Aging (Albany NY) 2009;1:12-16.
140. Michishita E, McCord RA, Berber E, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 2008;452:492-496. (Pubitemid 351450840)
141. Mostoslavsky R, Chua KF, Lombard DB, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006;124:315-329. (Pubitemid 43121980)
142. Grob A, Roussel P, Wright JE, et al. Involvement of SIRT7 in resumption of rDNA transcription at the exit from mitosis. J Cell Sci 2009;122:489-498.
143. Vakhrusheva O, Braeuer D, Liu Z, et al. Sirt7-dependent inhibition of cell growth and proliferation might be instrumental to mediate tissue integrity during aging. J Physiol Pharmacol 2008;59:201-212.
144. Jeong J, Juhn K, Lee H. et al. SIRT1 promotes DNA repair activity and deacetylation of Ku70. Exp Mol Med 2007;39:8-13. (Pubitemid 46356001)
145. Sun Y, Sun D, Li F, et al. Downregulation of SIRT1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Lung Cancer 2007;58:21-29. (Pubitemid 47385929)
146. Matsushita N, Takami Y, Kimura M, et al. Role of NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced cell death in vertebrate cells. Genes Cells 2005;10:321-332. (Pubitemid 40443684)
147. Liang XJ, Finkel T, Shen DW, et al. SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res 2008;6:1499-1506.
148. Fulda S, Debatin KM. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004;23:6702-6711. (Pubitemid 39280002)
149. Li Y, Bäckesjö CM, Haldosén LA, Lindgren U. Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells. Eur J Pharmacol 2009;609:13-18.
150. Morselli E, Galluzzi L, Kepp O, et al. Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol. Aging (Albany NY) 2009;1:961-970.
151. Morselli E, Maiuri MC, Markaki M, et al. The life span-prolonging effect of sirtuin-1 is mediated by autophagy. Autophagy 2010;6:186-188.
152. Yamamori T, DeRicco J, Naqvi A, et al. SIRT1 deacetylates APE1 and regulates cellular base excision repair. Nucleic Acids Res 2010;38:832-845.
153. Boily G, He XH, Pearce B, et al. SIRT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene 2009;28:2882-2893.